Peg-interferon for hepatitis B with fatty liver
Part of Digestive system, Infections clinical trials.
This trial tests a medicine called peg-interferon for people who have both chronic hepatitis B and fatty liver. It aims to see if the treatment is safe and effective in helping your body fight the hepatitis B virus.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 60 years old.
- You have chronic hepatitis B (HBsAg positive for more than 6 months) and also have fatty liver diagnosed by imaging.
- Your hepatitis B virus level is undetectable (negative HBV DNA).
- You are not currently pregnant, breastfeeding, or planning to become pregnant during the study.
- You do not have cirrhosis, other active hepatitis infections (A, C, D, E, HIV), or serious mental health conditions like depression.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a long-acting interferon medication can help people with chronic hepatitis B who have already received interferon treatment clear the hepatitis B virus more completely. It's designed for patients whose virus levels dropped significantly during their first treatment but haven't gone away.
This study tests a lower dose of pegylated interferon for people with chronic hepatitis B whose virus levels dropped significantly during a previous interferon treatment. It aims to see if a second round can further reduce or clear the virus.
This trial tests whether adding pegylated interferon alfa-2b can help people with hepatitis B stay virus-free after they stop their current oral antiviral medication. It is for patients who have had undetectable virus for over 3 years and have low levels of hepatitis B surface antigen.
This study tests whether adding a pegylated interferon (a medicine that boosts your immune system) to your current hepatitis B treatment can help lower your hepatitis B virus levels even more. It is for people with chronic hepatitis B who have not had interferon recently and do not have fatty liver disease.
This study tests whether additional peginterferon treatment can further reduce the virus in the liver for people with chronic hepatitis B who have already reached a clinical cure. You would need to have two liver biopsies to check the virus levels.
This study tests a new combination of antiviral medicine and an immune-boosting therapy for adults with chronic hepatitis B. It is designed for people who are in the active phase of the infection and have not been treated before.
Hear when a new Non-Alcoholic Fatty Liver Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.